Study of Subcutaneous Injection of Low-dose rhGM-CSF +/- WLL in PAP.

Study of Subcutaneous Injection of Low-dose Recombinant Granulocyte Macrophage-Colony Stimulating Factor (rhGM-CSF) +/- Whole Lung Lavage(WLL) in Pulmonary Alveolar Proteinosis.

The purpose of this study is to establish an efficient and economic treatment scheme by evaluation of the safety and efficacy of subcutaneous injection of low-dose rhGM-CSF, or of similar injection after whole lung lavage , in patients with PAP.

The purpose of this study is to establish an efficient and economic treatment scheme by evaluation of the safety and efficacy of subcutaneous injection of low-dose rhGM-CSF, or of similar injection after whole lung lavage , in patients with PAP. During the observation, study visits will occur at the end of each month. During the 1-year follow-up period which is lasting 6 months after the treatment, all participants will be required to check the various efficacy indicators.

Inclusion Criteria:

• Diagnosed PAP patients
• Aged 17-80
• Signed informed consent

Exclusion Criteria:

• Secondary PAP
• Received whole lung lavage therapy within 4 weeks before enrollment
• Received previous GM-CSF therapy within 6 months before enrollment
• WBC≥12,000/ul
• fever≥38℃
• Severe edema, severe liver, kidney, lung and cardiovascular disease.
• Pregnant，planning to get pregnant or nursing
• Inability to express the subjective discomfort
• Serious drug allergy history, E.coli preparation or rhGM-CSF serious allergy history